Novo and existing shareholder Novartis have contributed to a funding round that will allow antifungal drug developer F2G to advance its lead candidate.

Robert Bosch's corporate venturing unit recently launched a $170m third fund, and China and agribusiness startups are on the menu, according to managing director Ingo Ramesohl.

Novo-backed SI-Bone has added $20m to its coffers in a funding round led by Arboretum Ventures that featured all its major existing shareholders.

Takeda, which formed a strategic partnership agreement with Mersana in February, has taken part in a series C round to help the company expand its Fleximer platform.

Shenzhen Hepalink Pharmaceutical is set to inject capital into TPG Biotechnology Partners V, which focuses on the biomedical and life science sectors.

Johns Hopkins University spinout Blade Therapeutics has attracted $45m in commitments from investors including Pfizer, Novartis and Bristol-Myers Squibb.

Johns Hopkins University spinout Blade Therapeutics has attracted $45m in commitments from investors including Pfizer, Novartis and Bristol-Myers Squibb.

Phoenix Group has partnered Arkin Holdings to establish a strategic collaboration that will focus on pharmaceutical and biotechnology investments.

Novo and Sofinnova Partners have co-led a series B round for Rgenix, a spinout of Rockefeller University that hopes to enter two immunotherapies into clinical trials this autumn.